First-line PD-1 blockades combined with TKIs for metastatic non-clear cell renal cell carcinoma: a real-world multicenter retrospective study

Key Points

• Patients receiving PD-1 blockade alongside TKIs show improved responses and overall survival rates.
• Data reveals that combining therapies can optimize treatment for metastatic renal cell carcinoma.
• Retrospective analysis across multiple centers provides a broad insight into real-world effectiveness.
• Findings suggest a potential new standard for treating this challenging cancer type.